Foghorn Therapeutics (FHTX) Tax Provisions (2023)

Foghorn Therapeutics' (FHTX) quarterly Tax Provisions came in at $2.0 million in Q4 2023, up 169.11% quarter-over-quarter from $738000.0 in Q3 2023.

Foghorn Therapeutics (FHTX) Tax Provisions (2023) Analysis & Trends

Foghorn Therapeutics' Tax Provisions history runs 1 years deep, the most recent figure standing at $2.0 million for Q4 2023.

On a quarterly basis, Tax Provisions changed N/A year-over-year to $2.0 million in Q4 2023; TTM through Sep 2024 was $2.0 million, a 11.34% decrease from a year earlier, with the FY2023 full-year figure at $4.2 million, changed N/A from the prior year.
Tax Provisions grew to $2.0 million in Q4 2023 per FHTX's latest filing, from $738000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $2.0 million in Q4 2023 and bottomed at $560000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	125,146.46
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	31.86 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	179.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Foghorn Therapeutics	352.57 Mn	263.66 Mn	-	-

Download Data